Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension
Open Access
- 29 January 1998
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 338 (5) , 273-277
- https://doi.org/10.1056/nejm199801293380501
Abstract
Primary (idiopathic) pulmonary hypertension is a progressive, fatal disease. Conventional therapy with anticoagulant and vasodilator drugs may improve symptoms and survival among selected patients, but there is no evidence that the disease can be reversed.Keywords
This publication has 16 references indexed in Scilit:
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Pharmacodynamic profile of prostacyclinThe American Journal of Cardiology, 1995
- Comparative Acute Effects of Adenosine and Prostacyclin in Primary Pulmonary HypertensionChest, 1995
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary HypertensionAmerican Review of Respiratory Disease, 1989
- Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.Circulation, 1989
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987
- Pharmacologically induced Pulmonary Vasodilatation in Children and Young Adults with Primary Pulmonary HypertensionChest, 1986
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984
- Primary Pulmonary HypertensionCirculation, 1970